Needham lowered the firm’s price target on Jazz Pharmaceuticals to $220 from $225 and keeps a Buy rating on the shares. The company missed on Q4 earnings due to higher R&D spend and tax rate, and the stock looks range-bound as investors look for visibility into long term growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAZZ:
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
- Jazz Pharmaceuticals Announces Board Changes and Appointments
- JAZZ Upcoming Earnings Report: What to Expect?
- Jazz Pharmaceuticals Welcomes New CFO with Strong Financial Expertise
- Jazz Pharmaceuticals appoints Philip Johnson as CFO
